Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer

Frontiers in Oncology

Oncology

Yi Sun¹  Dalu Kong²  Jiagang Han³  Zhigang Bai⁴  Zhongtao Zhang⁴  Xiao Zhang⁴  Qi Wei⁴  Hongwei Yao⁴  Wei Deng⁴  Jiale Gao⁴  Zhengyang Yang⁴  Yishan Liu⁴  Gang Liu⁵  Ang Li⁶  Rui Xu⁷  Guangyong Chen⁷  Jie Zhang⁸ 

[1] Department of Anorectal, Tianjin People’s Hospital, Tianjin, China;Department of Colorectal Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin’s Clinical Research Center for Cancer, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China;Department of General Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China;Department of General Surgery, Beijing Friendship Hospital, Capital Medical University & National Clinical Research Center for Digestive Diseases, Beijing, China;Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China;Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China;Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing, China;Department of Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China;

关键词: rectal cancer;    chemoradiotherapy;    immune checkpoint inhibitors;    neoadjuvant therapy;    combination therapy;   

DOI  :  10.3389/fonc.2023.1057947

 received in 2022-09-30, accepted in 2023-01-19,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundNeoadjuvant chemoradiotherapy is the standard treatment for locally advanced rectal cancer, with modest benefits on tumor regression and survival. Since chemoradiotherapy combined with immune checkpoint inhibitors has been reported to have synergic effects. This study aims to explore the safety and efficacy of long-course chemoradiotherapy combined with concurrent tislelizumab as a neoadjuvant treatment regimen for patients with locally advanced rectal cancer.MethodsThis manuscript reported the interim result of a prospective, multicenter, single-arm, phase II trial. Patients with mid-to-low locally advanced rectal cancer with clinical stages of cT3-4a N0M0 or cT1-4a N1-2M0 were included. The patients received long-course radiotherapy (50 Gy/25 f, 2 Gy/f, 5 days/week) and three 21-day cycles of capecitabine (1000 mg/m2, bid, day1-14) plus concurrent three 21-day cycles of tislelizumab (200 mg, day8), followed by a radical surgery 6-8 weeks after radiotherapy. The primary endpoint was the pathological complete response rate. (Clinical trial number: NCT04911517)ResultsA total of 26 patients completed the treatment protocol between April 2021 and June 2022. All patients completed chemoradiotherapy, 24 patients received three cycles of tislelizumab, and 2 patients received two cycles. The pathological complete remission (ypT0N0) was achieved in 50% (13/26) of the patients with all proficient mismatch repair tumors. The immune-related adverse event occurred in 19.2% (5/26) of patients. Patients with no CEA elevation or age less than 50 were more likely to benefit from this treatment regimen.ConclusionLong-course chemoradiotherapy combined with concurrent tislelizumab in patients with locally advanced low rectal cancer had favorable safety and efficacy, and does not increase the complication rate of surgery. Further study is needed to confirm these results.

【 授权许可】

Unknown   
Copyright © 2023 Gao, Zhang, Yang, Zhang, Bai, Deng, Chen, Xu, Wei, Liu, Han, Li, Liu, Sun, Kong, Yao and Zhang